المؤلفون: Lebellec, Loic, Bertucci, François, Tresch-Bruneel, Emmanuelle, Bompas, Emmanuelle, Toiron, Yves, Camoin, Luc, Mir, Olivier, Laurence, Valérie, Clisant-Delaine, Stephanie, Decoupigny, Emilie, Blay, Jean-Yves, Goncalves, Anthony, Penel, Nicolas

المساهمون: CHU Lille, Université de Lille, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Institut Paoli-Calmettes IPC, Site de Recherche Intégrée en Cancérologie SIRIC-ONCOLille, Centre René Gauducheau, Institut Gustave Roussy IGR, Institut Curie Paris, 116612, Centre Léon Bérard Lyon, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 METRICS

مصطلحات موضوعية: biomarker, placental growth factor, sorafenib, chordoma, vascular endothelial growth factor, Mesh:Protein Kinase Inhibitors/therapeutic use, Mesh:Chordoma/drug therapy, Mesh:Chordoma/blood, Mesh:Biomarkers, Mesh:Tumor, Mesh:Antineoplastic Agents/therapeutic use, Mesh:Aged, Mesh:80 and over, Mesh:Neoplasm Staging, Mesh:Neoplasm Metastasis, Mesh:Middle Aged, Mesh:Membrane Proteins/blood, Mesh:Male, Mesh:Kaplan-Meier Estimate, Mesh:Humans, Mesh:Niacinamide/analogs & derivatives, Mesh:Female, Mesh:Combined Modality Therapy, Mesh:Clinical Trials, Mesh:Phase II as Topic, Mesh:Niacinamide/therapeutic use, Mesh:Phenylurea Compounds/therapeutic use, Mesh:Prognosis, Mesh:Adult, Mesh:Chordoma/pathology

وصف الملف: application/octet-stream; application/rdf+xml; charset=utf-8; application/pdf

Relation: Oncotarget; http://hdl.handle.net/20.500.12210/17132

الاتاحة: https://hdl.handle.net/20.500.12210/17132

المؤلفون: Eroukhmanoff, Juliette, Castinetti, Frederic, Penel, Nicolas, Salas, Sébastien

المساهمون: CHU Lille, Université de Lille, 547835, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 METRICS

مصطلحات موضوعية: Chordoma, Auto-immune thyroid dysfunction, Tyrosine kinase inhibitors, Mesh:Phenylurea Compounds/adverse effects, Mesh:Graves Disease/chemically induced, Mesh:Humans, Mesh:Imatinib Mesylate/adverse effects, Mesh:Male, Mesh:Middle Aged, Mesh:Neoplasm Recurrence, Mesh:Local/drug therapy, Mesh:Niacinamide/adverse effects, Mesh:Chordoma/drug therapy, Mesh:Antineoplastic Agents/adverse effects, Mesh:Protein Kinase Inhibitors/adverse effects, Mesh:Niacinamide/analogs & derivatives

وصف الملف: application/octet-stream; application/rdf+xml; charset=utf-8; application/pdf

Relation: BMC Cancer; http://hdl.handle.net/20.500.12210/17119

الاتاحة: https://hdl.handle.net/20.500.12210/17119

المؤلفون: Lebellec, Loic, Bertucci, François, Tresch-Bruneel, Emmanuelle, Bompas, Emmanuelle, Toiron, Yves, Camoin, Luc, Mir, Olivier, Laurence, Valérie, Clisant-Delaine, Stephanie, Decoupigny, Emilie, Blay, Jean-Yves, Goncalves, Anthony, Penel, Nicolas

المساهمون: CHU Lille, Université de Lille, Institut Paoli-Calmettes, Site de Recherche Intégrée en Cancérologie SIRIC-ONCOLille, Centre René Gauducheau, Institut Gustave Roussy IGR, Institut Curie Paris, 116612, Centre Léon Bérard Lyon, Santé publique : épidémiologie et qualité des soins - EA 2694

مصطلحات موضوعية: biomarker, placental growth factor, sorafenib, chordoma, vascular endothelial growth factor, Mesh:Protein Kinase Inhibitors/therapeutic use, Mesh:Chordoma/drug therapy, Mesh:Chordoma/blood, Mesh:Biomarkers, Mesh:Tumor, Mesh:Antineoplastic Agents/therapeutic use, Mesh:Aged, Mesh:80 and over, Mesh:Neoplasm Staging, Mesh:Neoplasm Metastasis, Mesh:Middle Aged, Mesh:Membrane Proteins/blood, Mesh:Male, Mesh:Kaplan-Meier Estimate, Mesh:Humans, Mesh:Niacinamide/analogs & derivatives, Mesh:Female, Mesh:Combined Modality Therapy, Mesh:Clinical Trials, Mesh:Phase II as Topic, Mesh:Niacinamide/therapeutic use, Mesh:Phenylurea Compounds/therapeutic use, Mesh:Prognosis, Mesh:Adult, Mesh:Chordoma/pathology

وصف الملف: application/octet-stream; application/rdf+xml; charset=utf-8; application/pdf

Relation: Oncotarget; http://hdl.handle.net/20.500.12210/17132.3

الاتاحة: https://hdl.handle.net/20.500.12210/17132.3

المؤلفون: Eroukhmanoff, Juliette, Castinetti, Frederic, Penel, Nicolas, Salas, Sébastien

المساهمون: CHU Lille, Université de Lille, 547835, Santé publique : épidémiologie et qualité des soins - EA 2694

مصطلحات موضوعية: Chordoma, Auto-immune thyroid dysfunction, Tyrosine kinase inhibitors, Mesh:Phenylurea Compounds/adverse effects, Mesh:Graves Disease/chemically induced, Mesh:Humans, Mesh:Imatinib Mesylate/adverse effects, Mesh:Male, Mesh:Middle Aged, Mesh:Neoplasm Recurrence, Mesh:Local/drug therapy, Mesh:Niacinamide/adverse effects, Mesh:Chordoma/drug therapy, Mesh:Antineoplastic Agents/adverse effects, Mesh:Protein Kinase Inhibitors/adverse effects, Mesh:Niacinamide/analogs & derivatives

وصف الملف: application/pdf; application/rdf+xml; charset=utf-8; application/octet-stream

Relation: BMC Cancer; http://hdl.handle.net/20.500.12210/17119.2

الاتاحة: https://hdl.handle.net/20.500.12210/17119.2